shRNA Inhibiting TUBB2B Expression in Triple-Negative Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for triple-negative breast cancer (TNBC) lack effective targeted therapies, leading to poor outcomes and high toxicity, with TUBB2B overexpression contributing to aggressive phenotypes and poor prognosis.
Innovation Solution
Designing short hairpin RNA (shRNA) molecules that inhibit TUBB2B expression through RNA interference, using lentiviral vectors or gold nanoparticles to deliver RNAi molecules targeting the TUBB2B gene, potentially combined with other therapeutic agents like PI3K/Akt pathway inhibitors or chemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat triple-negative breast cancer, then tumor cells are killed, but life-threatening toxicity occurs
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (TUBB2B protein function in microtubule dynamics) that drives cancer cell survival and proliferation. By designing shRNA to specifically silence TUBB2B gene expression, the treatment selectively attacks cancer cells overexpressing this gene while sparing normal cells that rely on other beta-tubulin isoforms, thereby reducing off-target toxicity compared to conventional chemotherapy.
Solution Approach 2:
The patent introduces shRNA as an intermediary molecule that mediates gene silencing through the RNA interference pathway. This intermediary approach allows for precise molecular targeting of TUBB2B mRNA, converting it into double-stranded RNA that triggers selective degradation, thereby achieving cancer cell killing through a more specific and less toxic mechanism than direct chemical attack on all dividing cells.
2Reliability
If conventional treatments are used for TNBC, then some tumor control is achieved, but poor prognosis results due to lack of effective targeted therapy
Solution Approach 1:
The patent applies local quality by designing shRNA sequences with high specificity for TUBB2B mRNA. The short hairpin RNA is engineered to hybridize only to the unique sequence of TUBB2B transcripts, creating localized and precise gene silencing at the molecular level. This ensures that only cells overexpressing TUBB2B (primarily TNBC cells) are affected, while other breast cancer subtypes and normal tissues remain unaffected.
Solution Approach 2:
The patent replaces the mechanical/cellular-level action of conventional chemotherapy (non-specific cell killing) with a molecular-level mechanism (RNA interference). By substituting the broad-spectrum cytotoxic mechanism with a sequence-specific gene silencing approach, the treatment achieves superior targeting precision while maintaining effective tumor control in TUBB2B-positive TNBC.
3Reliability
If TUBB2B is inhibited by shRNA, then cancer cell growth is suppressed and apoptosis is induced, but delivery efficiency must be optimized
Solution Approach 1:
The patent uses lentiviral vectors as intermediary delivery vehicles to transport shRNA into cancer cells. The lentiviral system acts as a mediator that efficiently transduces dividing and non-dividing cells, enabling sustained intracellular expression of the therapeutic shRNA. This viral intermediary overcomes the challenge of delivering naked RNA molecules while maintaining immunogenicity at acceptable levels through pseudotyping and optimization.
Solution Approach 2:
The patent employs shRNA sequences that are transcribed from DNA templates within the lentiviral vector. The shRNA is essentially a copied and expressed version of the therapeutic sequence, allowing for stable integration and continuous production of the silencing molecule within the target cell. This copying mechanism ensures sustained therapeutic effect without requiring repeated administrations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The shRNA approach effectively reduces TUBB2B expression, inducing apoptosis in breast cancer cells with less toxicity than traditional chemotherapy, demonstrating promise for treating TNBC and other cancers with TUBB2B overexpression.
Implementation Method 1
a RNA interference (RNAi) molecule, where the RNAi molecule hybridizes to a target sequence on an mRNA of TUBB2B gene
Data Source
AI summary
This invention provides a designed short hairpin RNA (shRNA) containing RNA interference (RNAi) molecules. RNAi molecules hybridizes to a certain sequence of mRNA of TUBB2B. This invention develops a method of inhibiting TUBB2B expression in mammalian cell and a method of treating or controlling a cancer or tumor mediated by TUBB2B overexpression, including the step of administering a shRNA into a subject.